================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report: July 20, 2006
Date of earliest event reported: July 20, 2006
PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware 1-3619 13-5315170
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
235 East 42nd Street
New York, New York 10017
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 573-2323
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the obligation of the registrant under any of the
following provisions:
[ ] Written communication pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2 (b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 2.02 Results of Operations and Financial Condition
On July 20, 2006, Pfizer Inc. ("Pfizer") issued a press release announcing its
financial results for the second quarter of 2006. The information contained in
the press release is deemed to be "filed" under the Securities Exchange Act of
1934 as Exhibit 99 to this report, and such press release is incorporated herein
by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit 99 - Press Release of Pfizer Inc. dated July 20, 2006, reporting
Pfizer's financial results for the second quarter of 2006.
Exhibit 99 is deemed to be "filed" under the Securities Exchange
Act of 1934 in this Current Report on Form 8-K.
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the authorized undersigned.
PFIZER INC.
By: /S/ Margaret M. Foran
-------------------------------------------
Margaret M. Foran
Title: Senior Vice President-Corporate Governance,
Associate General Counsel and
Corporate Secretary
Dated: July 20, 2006
EXHIBIT INDEX
Exhibit No. Description
----------- -----------------------------------------------------------------
99 Press Release of Pfizer Inc. dated July 20, 2006, reporting
Pfizer's financial results for the second quarter of 2006.